Platinum Investment Management Ltd. Purchases Shares of 1,538,247 ProQR Therapeutics (NASDAQ:PRQR)

Platinum Investment Management Ltd. purchased a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,538,247 shares of the biopharmaceutical company’s stock, valued at approximately $4,076,000. Platinum Investment Management Ltd. owned 1.88% of ProQR Therapeutics as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. M&T Bank Corp bought a new stake in shares of ProQR Therapeutics during the 4th quarter valued at about $330,000. BNP Paribas Financial Markets grew its stake in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the period. OneDigital Investment Advisors LLC grew its stake in shares of ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares during the period. Ballentine Partners LLC bought a new stake in shares of ProQR Therapeutics during the 4th quarter valued at about $61,000. Finally, Raymond James Financial Inc. bought a new stake in shares of ProQR Therapeutics during the 4th quarter valued at about $260,000. 32.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PRQR has been the topic of a number of analyst reports. HC Wainwright lifted their price objective on ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, March 14th. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Oppenheimer initiated coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price objective on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

ProQR Therapeutics Trading Down 3.5 %

NASDAQ PRQR opened at $1.64 on Wednesday. The stock’s 50 day moving average is $2.21 and its 200 day moving average is $2.62. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62. The stock has a market cap of $133.96 million, a PE ratio of -5.13 and a beta of 0.24.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).